Brokerages expect bluebird bio Inc (NASDAQ:BLUE) to report earnings per share (EPS) of ($2.80) for the current fiscal quarter, Zacks reports. Nine analysts have provided estimates for bluebird bio’s earnings, with the lowest EPS estimate coming in at ($3.29) and the highest estimate coming in at ($2.31). bluebird bio reported earnings of ($2.31) per share in the same quarter last year, which would indicate a negative year over year growth rate of 21.2%. The company is expected to issue its next quarterly earnings report on Wednesday, May 1st.
According to Zacks, analysts expect that bluebird bio will report full year earnings of ($11.62) per share for the current fiscal year, with EPS estimates ranging from ($13.11) to ($9.19). For the next year, analysts forecast that the business will report earnings of ($10.45) per share, with EPS estimates ranging from ($13.76) to ($5.13). Zacks’ EPS averages are an average based on a survey of sell-side analysts that follow bluebird bio.
bluebird bio (NASDAQ:BLUE) last posted its earnings results on Thursday, February 21st. The biotechnology company reported ($2.72) EPS for the quarter, topping the consensus estimate of ($2.83) by $0.11. The firm had revenue of $19.20 million during the quarter, compared to analysts’ expectations of $9.06 million. bluebird bio had a negative net margin of 1,018.02% and a negative return on equity of 32.15%. bluebird bio’s quarterly revenue was up 357.1% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($2.52) EPS.
Shares of NASDAQ:BLUE opened at $137.06 on Thursday. The company has a market capitalization of $7.53 billion, a PE ratio of -12.83 and a beta of 2.62. bluebird bio has a twelve month low of $87.49 and a twelve month high of $199.70.
In related news, insider Jeffrey T. Walsh sold 1,500 shares of the stock in a transaction that occurred on Wednesday, April 10th. The shares were sold at an average price of $156.65, for a total transaction of $234,975.00. Following the completion of the sale, the insider now directly owns 42,421 shares of the company’s stock, valued at $6,645,249.65. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Kory James Wentworth sold 209 shares of the stock in a transaction that occurred on Monday, January 28th. The shares were sold at an average price of $125.96, for a total transaction of $26,325.64. Following the sale, the insider now directly owns 4,403 shares of the company’s stock, valued at $554,601.88. The disclosure for this sale can be found here. Over the last three months, insiders have sold 30,289 shares of company stock valued at $4,510,615. Company insiders own 3.00% of the company’s stock.
A number of hedge funds have recently added to or reduced their stakes in the stock. FMR LLC lifted its stake in bluebird bio by 1.0% during the fourth quarter. FMR LLC now owns 8,204,161 shares of the biotechnology company’s stock valued at $813,853,000 after purchasing an additional 80,474 shares during the last quarter. Vanguard Group Inc. lifted its position in shares of bluebird bio by 10.1% in the 3rd quarter. Vanguard Group Inc. now owns 4,619,413 shares of the biotechnology company’s stock valued at $674,435,000 after acquiring an additional 422,866 shares in the last quarter. Vanguard Group Inc lifted its position in shares of bluebird bio by 10.1% in the 3rd quarter. Vanguard Group Inc now owns 4,619,413 shares of the biotechnology company’s stock valued at $674,435,000 after acquiring an additional 422,866 shares in the last quarter. BlackRock Inc. lifted its position in shares of bluebird bio by 1.2% in the 4th quarter. BlackRock Inc. now owns 2,986,142 shares of the biotechnology company’s stock valued at $296,223,000 after acquiring an additional 34,053 shares in the last quarter. Finally, First Trust Advisors LP lifted its position in shares of bluebird bio by 24.3% in the 4th quarter. First Trust Advisors LP now owns 747,929 shares of the biotechnology company’s stock valued at $74,195,000 after acquiring an additional 146,046 shares in the last quarter.
bluebird bio Company Profile
bluebird bio, Inc, a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic diseases and cancer. Its product candidates in severe genetic diseases include LentiGlobin, which is in various clinical studies for the treatment of transfusion-dependent ß-thalassemia and severe sickle cell disease; and Lenti-D that is in Phase II/III clinical trials for the treatment of cerebral adrenoleukodystrophy, a rare hereditary neurological disorder.
Featured Article: Diluted Earnings Per Share
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.